Royalty Pharma plc Diluted Shares Outstanding (Weighted Average)
Royalty Pharma plc (RPRX) reported Diluted Shares Outstanding (Weighted Average) of 556.90 million shares for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding · last filed 2026-08-05
- Royalty Pharma plc weighted average number of shares outstanding, diluted for the quarter ending 2026-06-30 was 556.90M shares, a 0.96% decline year-over-year.
- Royalty Pharma plc weighted average number of shares outstanding, diluted for the quarter ending 2026-03-31 was 556.84M shares, a 3.68% decline year-over-year.
- Royalty Pharma plc weighted average number of shares outstanding, diluted for the quarter ending 2025-12-31 was 557.56M shares, a 5.40% decline year-over-year.
- Royalty Pharma plc weighted average number of shares outstanding, diluted for the quarter ending 2025-09-30 was 559.61M shares, a 5.59% decline year-over-year.
- Royalty Pharma plc weighted average number of shares outstanding, diluted for fiscal 2025 was 564.46M shares, a 4.99% decline from fiscal 2024.
- Royalty Pharma plc weighted average number of shares outstanding, diluted for fiscal 2024 was 594.11M shares, a 1.46% decline from fiscal 2023.
- Royalty Pharma plc weighted average number of shares outstanding, diluted for fiscal 2023 was 602.90M shares, a 37.66% increase from fiscal 2022.
- Royalty Pharma plc weighted average number of shares outstanding, diluted for fiscal 2022 was 437.97M shares, a 5.59% increase from fiscal 2021.
| Period end | Weighted Average Number of Shares Outstanding, Diluted 3 month | Weighted Average Number of Shares Outstanding, Diluted 6 month | Weighted Average Number of Shares Outstanding, Diluted 9 month | Weighted Average Number of Shares Outstanding, Diluted 12 month |
|---|---|---|---|---|
| 2026-06-30 | 556.90M shares 10-Q · filed 2026-08-05 | 557.35M shares 10-Q · filed 2026-08-05 | 557.10M shares derived: average of 3 quarters · filed 2026-08-05 | 557.73M shares derived: average of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | 556.84M shares 10-Q · filed 2026-05-06 | 557.20M shares derived: average of 2 quarters · filed 2026-05-06 | 558.00M shares derived: average of 3 quarters · filed 2026-05-06 | 559.08M shares derived: average of 4 quarters · filed 2026-08-05 |
| 2025-12-31 | 557.56M shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-11 | 558.58M shares derived: average of 2 quarters · filed 2026-02-11 | 559.82M shares derived: average of 3 quarters · filed 2026-08-05 | 564.46M shares 10-K · filed 2026-02-11 |
| 2025-09-30 | 559.61M shares 10-Q · filed 2025-11-05 | 560.95M shares derived: average of 2 quarters · filed 2026-08-05 | 566.75M shares 10-Q · filed 2025-11-05 | 572.35M shares derived: average of 4 quarters · filed 2026-08-05 |
| 2025-06-30 | 562.30M shares 10-Q · filed 2026-08-05 | 570.16M shares 10-Q · filed 2026-08-05 | 576.59M shares derived: average of 3 quarters · filed 2026-08-05 | 580.63M shares derived: average of 4 quarters · filed 2026-08-05 |
| 2025-03-31 | 578.10M shares 10-Q · filed 2026-05-06 | 583.74M shares derived: average of 2 quarters · filed 2026-05-06 | 586.74M shares derived: average of 3 quarters · filed 2026-05-06 | 589.28M shares derived: average of 4 quarters · filed 2026-05-06 |
| 2024-12-31 | 589.38M shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-11 | 591.05M shares derived: average of 2 quarters · filed 2026-02-11 | 593.01M shares derived: average of 3 quarters · filed 2026-02-11 | 594.11M shares 10-K · filed 2026-02-11 |
| 2024-09-30 | 592.73M shares 10-Q · filed 2025-11-05 | 594.82M shares derived: average of 2 quarters · filed 2025-11-05 | 595.68M shares 10-Q · filed 2025-11-05 | 596.14M shares derived: average of 4 quarters · filed 2026-02-11 |
| 2024-06-30 | 596.91M shares 10-Q · filed 2025-08-06 | 597.20M shares 10-Q · filed 2025-08-06 | 597.28M shares derived: average of 3 quarters · filed 2026-02-11 | 598.24M shares derived: average of 4 quarters · filed 2026-02-11 |
| 2024-03-31 | 597.48M shares 10-Q · filed 2025-05-08 | 597.46M shares derived: average of 2 quarters · filed 2026-02-11 | 598.69M shares derived: average of 3 quarters · filed 2026-02-11 | 600.48M shares derived: average of 4 quarters · filed 2026-02-11 |
| 2023-12-31 | 597.45M shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-11 | 599.29M shares derived: average of 2 quarters · filed 2026-02-11 | 601.48M shares derived: average of 3 quarters · filed 2026-02-11 | 602.90M shares 10-K · filed 2026-02-11 |
| 2023-09-30 | 601.14M shares 10-Q · filed 2024-11-06 | 603.50M shares derived: average of 2 quarters · filed 2024-11-06 | 604.72M shares 10-Q · filed 2024-11-06 | 436.13M shares derived: average of 4 quarters · filed 2025-02-12 |
| 2023-06-30 | 605.86M shares 10-Q · filed 2024-08-08 | 606.55M shares 10-Q · filed 2024-08-08 | 381.12M shares derived: average of 3 quarters · filed 2025-02-12 | 437.65M shares derived: average of 4 quarters · filed 2025-02-12 |
| 2023-03-31 | 607.25M shares 10-Q · filed 2024-05-09 | 268.76M shares derived: average of 2 quarters · filed 2025-02-12 | 381.58M shares derived: average of 3 quarters · filed 2025-02-12 | 437.99M shares derived: average of 4 quarters · filed 2025-02-12 |
| 2022-12-31 | -69.74M shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-12 | 268.74M shares derived: average of 2 quarters · filed 2025-02-12 | 381.57M shares derived: average of 3 quarters · filed 2025-02-12 | 437.97M shares 10-K · filed 2025-02-12 |
| 2022-09-30 | 607.23M shares 10-Q · filed 2023-11-08 | 607.22M shares derived: average of 2 quarters · filed 2023-11-08 | 607.21M shares 10-Q · filed 2023-11-08 | 414.85M shares derived: average of 4 quarters · filed 2024-02-15 |
| 2022-06-30 | 607.21M shares 10-Q · filed 2023-08-08 | 607.21M shares 10-Q · filed 2023-08-08 | 350.72M shares derived: average of 3 quarters · filed 2024-02-15 | 414.84M shares derived: average of 4 quarters · filed 2024-02-15 |
| 2022-03-31 | 607.20M shares 10-Q · filed 2023-05-09 | 222.48M shares derived: average of 2 quarters · filed 2024-02-15 | 350.71M shares derived: average of 3 quarters · filed 2024-02-15 | 414.82M shares derived: average of 4 quarters · filed 2024-02-15 |
| 2021-12-31 | -162.25M shares derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-15 | 222.46M shares derived: average of 2 quarters · filed 2024-02-15 | 350.70M shares derived: average of 3 quarters · filed 2024-02-15 | 414.80M shares 10-K · filed 2024-02-15 |
| 2021-09-30 | 607.17M shares 10-Q · filed 2022-11-08 | 607.17M shares derived: average of 2 quarters · filed 2022-11-08 | 607.15M shares 10-Q · filed 2022-11-08 | 555.01M shares derived: average of 4 quarters · filed 2023-02-15 |
| 2021-06-30 | 607.16M shares 10-Q · filed 2022-08-04 | 607.15M shares 10-Q · filed 2022-08-04 | 537.62M shares derived: average of 3 quarters · filed 2023-02-15 | 495.72M shares derived: average of 4 quarters · filed 2023-02-15 |
| 2021-03-31 | 607.15M shares 10-Q · filed 2022-05-05 | 502.85M shares derived: average of 2 quarters · filed 2023-02-15 | 458.57M shares derived: average of 3 quarters · filed 2023-02-15 | 432.42M shares derived: average of 4 quarters · filed 2023-02-15 |
| 2020-12-31 | 398.55M shares derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-15 | 384.28M shares derived: average of 2 quarters · filed 2023-02-15 | 374.18M shares derived: average of 3 quarters · filed 2023-02-15 | 375.45M shares 10-K · filed 2023-02-15 |
| 2020-09-30 | 370.00M shares 10-Q · filed 2021-11-10 | 361.99M shares derived: average of 2 quarters · filed 2021-11-10 | 367.76M shares 10-Q · filed 2021-11-10 | |
| 2020-06-30 | 353.98M shares 10-Q · filed 2021-08-11 | 353.98M shares 10-Q · filed 2021-08-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |